{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:21:27Z","timestamp":1765610487431,"version":"3.37.3"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T00:00:00Z","timestamp":1718496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015396","name":"Thailand Center of Excellence for Life Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejps.2024.106834","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T23:37:04Z","timestamp":1718840224000},"page":"106834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Preclinical characterization of a novel potent core protein assembly modulator for the treatment of chronic hepatitis B viral infection"],"prefix":"10.1016","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9884-5022","authenticated-orcid":false,"given":"Wilasinee","family":"Dunkoksung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udomsak","family":"Udomnilobol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanachote","family":"Ruengsatra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natthaya","family":"Chauypen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomayant","family":"Prueksaritanont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejps.2024.106834_bib0001","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1208\/s12248-020-00501-9","article-title":"Investigating the theoretical basis for in vitro-in vivo extrapolation (IVIVE) in predicting drug metabolic clearance and proposing future experimental pathways","volume":"22","author":"Benet","year":"2021","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2024.106834_bib0002","doi-asserted-by":"crossref","first-page":"e00560","DOI":"10.1128\/AAC.00560-17","article-title":"Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus","volume":"61","author":"Berke","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.ejps.2024.106834_bib0003","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nrd3845","article-title":"Reducing safety-related drug attrition: the use of in vitro pharmacological profiling","volume":"11","author":"Bowes","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejps.2024.106834_bib0004","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/S1473-3099(15)00436-3","article-title":"New therapeutic agents for chronic hepatitis B","volume":"16","author":"Brahmania","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejps.2024.106834_bib0005","series-title":"AASLD","first-page":"12","article-title":"Amino acid substitutions in the inhibitor binding pocket of HBV core protein confer differential changes in susceptibility to three generations of HBV core inhibitors","author":"Cai","year":"2020"},{"key":"10.1016\/j.ejps.2024.106834_bib0006","series-title":"EASL","article-title":"Discovery and preclinical profile of VNRX-9945, a potent, broadly active core protein inhibitor for the treatment of chronic hepatitis B virus (HBV) infection","author":"Coburn","year":"2021"},{"key":"10.1016\/j.ejps.2024.106834_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.766534","article-title":"In Vivo mouse models for hepatitis B virus infection and their application","volume":"12","author":"Du","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejps.2024.106834_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(23)03317-2","article-title":"Hepatitis B virus core protein variant profiles observed in chronic hepatitis B patients treated with capsid inhibitor AB-836","author":"Espiritu","year":"2023","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.ejps.2024.106834_bib0009","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1097\/HEP.0000000000000431","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV treatment endpoints conference","volume":"78","author":"Ghany","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ejps.2024.106834_bib0010","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1208\/s12248-008-9019-6","article-title":"Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates","volume":"10","author":"Harper","year":"2008","journal-title":"AAPS J."},{"year":"2024","series-title":"Clinical Trials for Hepatitis B","key":"10.1016\/j.ejps.2024.106834_bib0011"},{"issue":"11","key":"10.1016\/j.ejps.2024.106834_bib0012","doi-asserted-by":"crossref","first-page":"e01463","DOI":"10.1128\/AAC.01463-20","article-title":"Preclinical profile and characterization of the hepatitis B virus core protein inhibitor ABI-H0731","volume":"64","author":"Huang","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.ejps.2024.106834_bib0013","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/nprot.2007.303","article-title":"Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers","volume":"2","author":"Hubatsch","year":"2007","journal-title":"Nat. Protoc."},{"issue":"1","key":"10.1016\/j.ejps.2024.106834_bib0014","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","article-title":"Immunobiology and pathogenesis of hepatitis B virus infection","volume":"22","author":"Iannacone","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.ejps.2024.106834_bib0015","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1136\/gutjnl-2022-328041","article-title":"Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection","volume":"72","author":"Janssen","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2024.106834_bib0016","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejps.2024.106834_bib0017","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12916-023-02814-w","article-title":"Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial","volume":"21","author":"Jia","year":"2023","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.ejps.2024.106834_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/acs.chemrestox.8b00213","article-title":"Chemicals and drugs forming reactive quinone and quinone imine metabolites","volume":"32","author":"Klopcic","year":"2019","journal-title":"Chem. Res. Toxicol."},{"issue":"1","key":"10.1016\/j.ejps.2024.106834_bib0019","first-page":"e01734","article-title":"Preclinical characterization of NVR 3-778, a first-in-class capsid assembly modulator against hepatitis B virus","volume":"63","author":"Lam","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.ejps.2024.106834_bib0020","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2024.106834_bib0021","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.3390\/biomedicines9111577","article-title":"The hepatitis B virus nucleocapsid\u2014dynamic compartment for infectious virus production and new antiviral target","volume":"9","author":"Niklasch","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejps.2024.106834_bib0022","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1080\/00498254.2021.1912438","article-title":"Evaluation of the drug-drug interaction potential for trazpiroben (TAK-906), a D2\/D3 receptor antagonist for gastroparesis, towards cytochrome P450s and transporters","volume":"6","author":"Nishihara","year":"2021","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.ejps.2024.106834_bib0023","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metab. Dispos."},{"issue":"17","key":"10.1016\/j.ejps.2024.106834_bib0024","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1093\/bioinformatics\/btz037","article-title":"SMARTCyp 3.0: enhanced cytochrome P450 site-of-metabolism prediction server","volume":"35","author":"Olsen","year":"2019","journal-title":"Bioinformatics"},{"issue":"41","key":"10.1016\/j.ejps.2024.106834_bib0025","doi-asserted-by":"crossref","first-page":"29004","DOI":"10.1039\/D3RA04720B","article-title":"Binding characteristics of pyrrole-scaffold hepatitis B virus capsid inhibitors and identification of novel potent compounds","volume":"13","author":"Ruengsatra","year":"2023","journal-title":"RSC Adv."},{"issue":"2","key":"10.1016\/j.ejps.2024.106834_bib0026","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11901-010-0041-7","article-title":"Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for treatment of chronic hepatitis B","volume":"9","author":"Sonneveld","year":"2010","journal-title":"Curr. Hepatitis Rep."},{"issue":"5","key":"10.1016\/j.ejps.2024.106834_bib0027","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3390\/jcm11051349","article-title":"Capsid assembly modulators as antiviral agents against HBV: molecular mechanisms and clinical perspectives","volume":"11","author":"Taverniti","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejps.2024.106834_bib0028","series-title":"EASL","article-title":"EDP-514, a Novel HBV core inhibitor with potent antiviral activity both in vitro and in vivo","author":"Vaine","year":"2019"},{"issue":"9","key":"10.1016\/j.ejps.2024.106834_bib0029","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/jac\/dkaa179","article-title":"Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A-H clinical isolates and core site-directed mutants in vitro","volume":"75","author":"Verbinnen","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"issue":"5","key":"10.1016\/j.ejps.2024.106834_bib0030","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3851\/IMP2152","article-title":"In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations","volume":"17","author":"Wang","year":"2012","journal-title":"Antivir. Ther."},{"issue":"1","key":"10.1016\/j.ejps.2024.106834_bib0031","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/cmi.2013.43","article-title":"A mouse model for HBV immunotolerance and immunotherapy","volume":"11","author":"Yang","year":"2014","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.ejps.2024.106834_bib0032","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2015.06.020","article-title":"Core protein: a pleiotropic keystone in the HBV lifecycle","volume":"121","author":"Zlotnick","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ejps.2024.106834_bib0033","series-title":"EASL","article-title":"A novel pyrazole HBV nucleocapsid formation inhibitor demonstrating high activity against HBV variants that are resistant to class I and class II core protein allosteric modulators","author":"Zhang","year":"2019"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724001465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724001465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T06:45:29Z","timestamp":1721976329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098724001465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":33,"alternative-id":["S0928098724001465"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106834","relation":{},"ISSN":["0928-0987"],"issn-type":[{"type":"print","value":"0928-0987"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical characterization of a novel potent core protein assembly modulator for the treatment of chronic hepatitis B viral infection","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106834","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106834"}}